Amarin Corp Plcuk (AMRN) Current Deferred Revenue (2013 - 2024)
Amarin Corp Plcuk (AMRN) posted quarterly Current Deferred Revenue of $4.4 million for Q1 2024, down 70.14% YoY from $14.9 million in Q2 2023, and down 8.27% sequentially from $4.8 million in Q4 2023.
Amarin Corp Plcuk (AMRN) Current Deferred Revenue (2013 - 2024) Analysis & Trends
Amarin Corp Plcuk has disclosed Current Deferred Revenue across 11 years of filings, most recently posting $4.4 million for Q1 2024.
- In Q1 2024, Current Deferred Revenue fell 70.14% year-over-year to $4.4 million; the TTM figure through Mar 2024 stood at $4.4 million (down 70.14% YoY), while the FY2023 annual figure was $4.8 million, down 68.4% from the prior year.
- Current Deferred Revenue retreated to $4.4 million in Q1 2024, from $4.8 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for AMRN reached as high as $21.8 million in Q1 2020 and fell as low as $4.4 million in Q1 2024.
- The 5-year median for Current Deferred Revenue is $16.3 million (2022), against an average of $14.5 million.
- Annual changes were most pronounced in 2020 — Current Deferred Revenue rose 8.15% — and 2024, when it plunged 70.14%.
- A 5-year view of Current Deferred Revenue shows it stood at $18.6 million in 2020, then slipped by 10.32% to $16.7 million in 2021, then retreated by 8.16% to $15.3 million in 2022, then sank by 68.4% to $4.8 million in 2023, then slipped by 8.27% to $4.4 million in 2024.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $4.4 million, $4.8 million, and $5.0 million for Q1 2024, Q4 2023, and Q3 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 4.45 Mn |
| Dec 31, 2023 | 4.85 Mn |
| Sep 30, 2023 | 4.97 Mn |
| Jun 30, 2023 | 5.36 Mn |
| Mar 31, 2023 | 14.90 Mn |
| Dec 31, 2022 | 15.35 Mn |
| Sep 30, 2022 | 15.70 Mn |
| Jun 30, 2022 | 16.01 Mn |
| Mar 31, 2022 | 16.34 Mn |
| Dec 31, 2021 | 16.71 Mn |
| Sep 30, 2021 | 17.13 Mn |
| Jun 30, 2021 | 17.97 Mn |
| Mar 31, 2021 | 17.97 Mn |
| Dec 31, 2020 | 18.63 Mn |
| Sep 30, 2020 | 18.91 Mn |
| Jun 30, 2020 | 20.21 Mn |
| Mar 31, 2020 | 21.81 Mn |
| Dec 31, 2019 | 20.85 Mn |
| Sep 30, 2019 | 19.58 Mn |
| Jun 30, 2019 | 19.74 Mn |